Haematologica · 2017 · 57 citations · 22 references
MedicineOncologyPediatricsPediatric HematologyPediatric OncologySurvival AnalysisChild MortalityPediatric LeukemiasSurvival OutcomesChronic LeukemiasChronic Myeloid Leukemia TherapyClinical Survival RatesPrognostic CriteriaPrognostic VariablesRevised International Prognostic Scoring SystemSurvival Rates
The EUTOS Long-Term Survival score was tested in 350 children with chronic myeloid leukemia in first chronic phase treated with imatinib and registered in the International Registry for Childhood Chronic Myeloid Leukemia. With a median follow up of 3 years (range, 1 month to 6 years) progression and/or death (whichever came first) occurred in 23 patients. For the entire cohort of patients the 5-year progression-free survival rate was 92% (95% CI: 87%–94%) and the 5-year survival accounting for chronic myeloid leukemia deaths was 97% (95% CI: 94%–99%). Of the 309 patients allocated to low (n=199), intermediate (n=68) and high (n=42) risk groups by the EUTOS Long-Term Survival score, events (progression and/or death) occurred in 6.0%, 8.8% and 26.2%, respectively. Estimates of the 5-year progression-free survival rates according to these three risk groups were 96% (95% CI: 92%–98%), 88% (95% CI: 76%–95%) and 67% (95% CI: 48%–81%), respectively. Differences in progression-free survival according to these risk groups were highly significant (P
22
Prognostic discrimination in "good-risk" chronic granulocytic leukemia
JE Sokal, Cox Eb, Michele Baccarani et al. · Blood · 1984 · 1K citations · Full text
Medicine, Hematology, Oncology +13
Andreas Hochhaus, Giuseppe Saglio, Timothy P. Hughes et al. · Leukemia · 2016 · 850 citations · Full text